Omnicell, Inc. (NASDAQ:OMCL) Stock Holdings Increased by Deutsche Bank AG

Deutsche Bank AG grew its position in shares of Omnicell, Inc. (NASDAQ:OMCL) by 23.0% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 52,493 shares of the company’s stock after buying an additional 9,822 shares during the period. Deutsche Bank AG owned about 0.11% of Omnicell worth $2,337,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. SG Americas Securities LLC boosted its holdings in Omnicell by 56.5% in the fourth quarter. SG Americas Securities LLC now owns 39,359 shares of the company’s stock worth $1,752,000 after purchasing an additional 14,202 shares during the period. Exchange Traded Concepts LLC lifted its position in shares of Omnicell by 6.7% in the 4th quarter. Exchange Traded Concepts LLC now owns 319,682 shares of the company’s stock worth $14,232,000 after buying an additional 20,031 shares during the last quarter. KBC Group NV lifted its position in shares of Omnicell by 60.8% in the 4th quarter. KBC Group NV now owns 2,057 shares of the company’s stock worth $92,000 after buying an additional 778 shares during the last quarter. SteelPeak Wealth LLC acquired a new position in shares of Omnicell in the 4th quarter valued at about $635,000. Finally, Sumitomo Mitsui Trust Group Inc. grew its position in shares of Omnicell by 93.3% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,450,416 shares of the company’s stock valued at $64,573,000 after buying an additional 699,925 shares during the last quarter. Institutional investors and hedge funds own 97.70% of the company’s stock.

Wall Street Analyst Weigh In

OMCL has been the topic of a number of recent research reports. Wells Fargo & Company raised shares of Omnicell from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $31.00 to $35.00 in a report on Wednesday, May 14th. Wall Street Zen raised Omnicell from a “hold” rating to a “buy” rating in a report on Tuesday. Benchmark dropped their target price on Omnicell from $62.00 to $40.00 and set a “buy” rating on the stock in a research report on Wednesday, May 7th. Finally, JPMorgan Chase & Co. lowered their price target on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a research report on Thursday, March 20th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Omnicell presently has an average rating of “Moderate Buy” and an average price target of $46.50.

Omnicell Stock Performance

Shares of OMCL opened at $28.84 on Friday. Omnicell, Inc. has a 52-week low of $22.66 and a 52-week high of $55.75. The firm has a market capitalization of $1.35 billion, a PE ratio of 106.82, a P/E/G ratio of 7.53 and a beta of 0.78. The firm has a 50-day moving average price of $31.03 and a 200 day moving average price of $38.96. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 0.13.

Omnicell (NASDAQ:OMCL) last released its earnings results on Tuesday, May 6th. The company reported $0.26 earnings per share for the quarter, topping analysts’ consensus estimates of $0.16 by $0.10. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. The firm had revenue of $269.67 million during the quarter, compared to the consensus estimate of $260.18 million. During the same period in the prior year, the firm posted $0.03 earnings per share. The firm’s revenue for the quarter was up 9.5% compared to the same quarter last year. On average, sell-side analysts anticipate that Omnicell, Inc. will post 1.09 earnings per share for the current fiscal year.

Omnicell Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.